Targeting immune heterogeneity in liver metastases through in vivo genetic engineering.

The liver is both a central metabolic organ and a uniquely tolerogenic immune niche, which makes it a frequent site of liver metastases (LMS) and a challenging environment for immunotherapy. It is increasingly appreciated that resident liver cells- K…

Preview only. Read the full abstract at the source